Enfusion’s chief people officer sells shares worth $23,696

Enfusion , Inc. (NYSE:ENFN) recently saw a transaction involving its Chief People Officer, Bastone Bronwen, who sold 2,064 shares of the company’s Class A common stock. The shares were sold at an average price of $11.481, amounting to a total value of $23,696. This transaction, dated March 3, 2025, was disclosed in a Form 4 filing with the Securities and Exchange Commission. The sale occurred as the stock trades near its 52-week high of $11.80, having gained over 41% in the past six months, according to InvestingPro data.

The sale was not a discretionary trade by Bronwen. Instead, it was conducted to cover tax withholding obligations related to the issuance of shares. Following this transaction, Bronwen retains ownership of 225,001 shares in Enfusion, maintaining significant exposure to the $1.47 billion market cap company.

The sale price for these shares varied between $11.429 and $11.535, according to the filing. Enfusion, headquartered in Chicago, operates in the prepackaged software industry, offering technology solutions to streamline investment management processes. The company maintains strong financials with a healthy current ratio of 3.42 and impressive revenue growth of 15.5% in the last twelve months, while achieving a robust gross margin of 67.8%. For deeper insights into Enfusion’s financial health and growth prospects, including 12 additional ProTips, check out the comprehensive analysis available on InvestingPro.

In other recent news, Enfusion Inc. announced its fourth-quarter results for 2024, coinciding with news of its acquisition by Clearwater Analytics at $11.25 per share. Stifel analysts maintained a Hold rating on Enfusion, with a price target of $11.25, matching the acquisition price. This follows a previous downgrade by Stifel from Buy to Hold, reflecting the acquisition’s influence on the stock’s valuation. Morgan Stanley (NYSE:MS) also adjusted its stance, downgrading Enfusion from Overweight to Equal-weight, while raising the price target to $11.25 to align with the acquisition offer.

The acquisition agreement marks a significant transition for Enfusion, with the agreed share price now serving as a benchmark for analysts and investors. According to Morgan Stanley, Enfusion’s performance has been at the lower end of expectations, and the acquisition is seen as a means to expedite value realization for shareholders. Stifel analysts noted that the acquisition price offers a 13% premium over the stock’s previous closing price, valuing the company at approximately 6.4 times its projected FY25 enterprise value/revenue.

The consensus among analysts is that the acquisition represents a fair outcome for Enfusion shareholders, with little expectation of a higher competing bid. This development is prompting investors to closely watch the situation as the market adjusts to the acquisition news.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.